E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome–negative acute lymphocytic leukemia
Hui Yang,Tapan M. Kadia,Lianchun Xiao,Carlos E. Bueso-Ramos,Koyu Hoshino,Deborah A. Thomas,Susan O'Brien,Elias Jabbour,Sherry Pierce,Gary L. Rosner,Hagop M. Kantarjian,Guillermo Garcia-Manero +11 more
TL;DR: In this article, the authors developed a bisulfite polymerase chain reaction (BPCR) assay and analyzed the methylation levels of p73, p15 and p57KIP2 at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL− ALL.
Journal ArticleDOI
Recent Advances in Adult Acute Lymphoblastic Leukemia.
TL;DR: Development of monoclonal antibodies, CAR T, and potent TKI has improved the outcome of ALL and combines with chemotherapy and their incorporation in the frontline setting show promises to improve cure rates of ALL.
Journal ArticleDOI
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
Tapan M. Kadia,Hagop M. Kantarjian,Deborah A. Thomas,Susan O'Brien,Zeev Estrov,Farhad Ravandi,Elias Jabbour,Naveen Pemmaraju,Naval Daver,Xuemei Wang,Preetesh Jain,Sherry Pierce,Mark Brandt,Guillermo Garcia-Manero,Jorge E. Cortes,Gautam Borthakur +15 more
TL;DR: A pilot trial combining methotrexate, vincristine, PEGylated‐asparaginase, and dexamethasone (MOpAD) in adults with relapsed or refractory ALL added tyrosine kinase inhibitors and rituximab in patients with CD20 positive B‐cell ALL to achieve complete remission.
Journal ArticleDOI
Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.
Elias Jabbour,Hagop M. Kantarjian,Deborah A. Thomas,Guillermo Garcia-Manero,Simon Abi Aad,Rebecca Garris,Jorge E. Cortes,Tapan M. Kadia,Farhad Ravandi,Srdan Verstovsek,Susan O'Brien +10 more
TL;DR: Ofatumumab targets a membrane proximal small-loop epitope on the CD20 molecule and was found to be more potent than rituximab and associated with better responses and higher 3-year PFS and OS rates.
Journal ArticleDOI
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).
Jorge E. Cortes,Elias Jabbour,Andreas Hochhaus,Philipp le Coutre,Michele Baccarani,Kapil N. Bhalla,Gert J. Ossenkoppele,Norbert Gattermann,Ariful Haque,Neil Gallagher,Francis J. Giles,Hagop M. Kantarjian +11 more
TL;DR: Results support nilotinib’s excellent tolerability and indicate that it can be used effectively in both CML-CP and -AP pts with imatinib-intolerant Ph+CML.